339 related articles for article (PubMed ID: 32630545)
1. HLA-G: A New Immune Checkpoint in Cancer?
Krijgsman D; Roelands J; Hendrickx W; Bedognetti D; Kuppen PJK
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630545
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.
Lin A; Yan WH
Front Immunol; 2018; 9():2164. PubMed ID: 30319626
[TBL] [Abstract][Full Text] [Related]
3. Cytokine stimulation of the choriocarcinoma cell line JEG-3 leads to alterations in the HLA-G expression profile.
Persson G; Bork JBS; Isgaard C; Larsen TG; Bordoy AM; Bengtsson MS; Hviid TVF
Cell Immunol; 2020 Jun; 352():104110. PubMed ID: 32387976
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
5. HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.
Lin A; Yan WH
Front Immunol; 2021; 12():698677. PubMed ID: 34276691
[TBL] [Abstract][Full Text] [Related]
6. The immunosuppressive molecule HLA-G and its clinical implications.
González A; Rebmann V; LeMaoult J; Horn PA; Carosella ED; Alegre E
Crit Rev Clin Lab Sci; 2012; 49(3):63-84. PubMed ID: 22537084
[TBL] [Abstract][Full Text] [Related]
7. The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?
Attia JVD; Dessens CE; van de Water R; Houvast RD; Kuppen PJK; Krijgsman D
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213057
[TBL] [Abstract][Full Text] [Related]
8. HLA-G1 and HLA-G5 isoforms have an additive effect on NK cytolysis.
Zhang WQ; Xu DP; Liu D; Li YY; Ruan YY; Lin A; Yan WH
Hum Immunol; 2014 Feb; 75(2):182-9. PubMed ID: 24269702
[TBL] [Abstract][Full Text] [Related]
9. HLA-G: An Immune Checkpoint Molecule.
Carosella ED; Rouas-Freiss N; Tronik-Le Roux D; Moreau P; LeMaoult J
Adv Immunol; 2015; 127():33-144. PubMed ID: 26073983
[TBL] [Abstract][Full Text] [Related]
10. [HLA-G: from feto-maternal tolerance to organ acceptance].
Carosella ED
Bull Acad Natl Med; 2014; 198(4-5):801-11; discussion 812. PubMed ID: 26753410
[TBL] [Abstract][Full Text] [Related]
11. HLA-G Neo-Expression on Tumors.
Loustau M; Anna F; Dréan R; Lecomte M; Langlade-Demoyen P; Caumartin J
Front Immunol; 2020; 11():1685. PubMed ID: 32922387
[TBL] [Abstract][Full Text] [Related]
12. HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy.
Palma MB; Tronik-Le Roux D; Amín G; Castañeda S; Möbbs AM; Scarafia MA; La Greca A; Daouya M; Poras I; Inda AM; Moro LN; Carosella ED; García MN; Miriuka SG
Sci Rep; 2021 Nov; 11(1):22158. PubMed ID: 34773056
[TBL] [Abstract][Full Text] [Related]
13. HLA-G and immune evasion in cancer cells.
Sheu J; Shih IeM
J Formos Med Assoc; 2010 Apr; 109(4):248-57. PubMed ID: 20434034
[TBL] [Abstract][Full Text] [Related]
14. The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016.
Rizzo R; Fainardi E; Rouas-Freiss N; Morandi F
J Immunol Res; 2017; 2017():2309574. PubMed ID: 28133618
[No Abstract] [Full Text] [Related]
15. Evaluation of the Reactivity and Receptor Competition of HLA-G Isoforms toward Available Antibodies: Implications of Structural Characteristics of HLA-G Isoforms.
Furukawa A; Meguro M; Yamazaki R; Watanabe H; Takahashi A; Kuroki K; Maenaka K
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779209
[TBL] [Abstract][Full Text] [Related]
16. Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.
Zheng G; Jia L; Yang AG
Front Immunol; 2022; 13():791975. PubMed ID: 35185887
[TBL] [Abstract][Full Text] [Related]
17. Human leukocyte antigen-G in gynaecological tumours.
Guo X; Zhang J; Shang J; Cheng Y; Tian S; Yao Y
Int J Immunogenet; 2023 Aug; 50(4):163-176. PubMed ID: 37415092
[TBL] [Abstract][Full Text] [Related]
18. HLA-G as a tolerogenic molecule in transplantation and pregnancy.
Rebmann V; da Silva Nardi F; Wagner B; Horn PA
J Immunol Res; 2014; 2014():297073. PubMed ID: 25143957
[TBL] [Abstract][Full Text] [Related]
19. HLA-G regulators in cancer medicine: an outline of key requirements.
Zidi I; Ben Amor N
Tumour Biol; 2011 Dec; 32(6):1071-86. PubMed ID: 21792710
[TBL] [Abstract][Full Text] [Related]
20. Galectin-1 influences trophoblast immune evasion and emerges as a predictive factor for the outcome of pregnancy.
Tirado-González I; Freitag N; Barrientos G; Shaikly V; Nagaeva O; Strand M; Kjellberg L; Klapp BF; Mincheva-Nilsson L; Cohen M; Blois SM
Mol Hum Reprod; 2013 Jan; 19(1):43-53. PubMed ID: 23002109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
